Patent · US Active

Human monoclonal antibody having fat-reducing effect

US9273125B2 · kind B2 · utility

1Cited by

12References

12Claims

0Family size

Assignee

Patrys Limited · AU

Inventor

Heinz Peter Vollmers · Coburg, DE

Key dates

Filing date	Feb 27, 2012
Grant date	Mar 1, 2016
Priority date	—
Expiry date	May 10, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/565
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Purified polypeptide is proposed, the amino acid sequence of which is essentially identical to the amino acid sequence of SEQ ID NO:1 and SEQ ID NO:3, the polypeptide binding low density lipoproteins (LDL) and/or oxidized LDL (oxLDL), in particular LDL cholesterol and/or oxidized LDL cholesterol (oxLDL cholesterol).The invention includes the use of the polypeptide in combination with conventional adjuvants and/or carrier substances for producing a drug having a fat-reducing effect and for producing drugs for treating renal diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.